Microneedling With Regular Insulin Versus Microneedling Alone in Treatment of Atrophic Scars

Status

Recruiting

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT06021275

Enrollment

Registered

2023-09-01

Start date

2023-10-01

Completion date

2024-12-31

Last updated

2024-07-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Insulin, Scars

Keywords

Insulin, scars

Brief summary

Recently, few studies have attempted to test the regenerative effects of human insulin application by microneedling on atrophic scars versus other topical preparations. However, the scars were limited etiologically to acne scars. In addition, a lack of inclusion of a control group instead of comparing topical preparations with insulin was also a limitation to these studies. A control group consisting of microneedling alone would have served as a better comparison in order to determine whether the effects of microneedling are augmented by topical protein-rich preparations.

Interventions

OTHERMicroneedling with topical application of regular insulin

Microneeling preformed onto the scar In one group insulin will be applied while saline will be used in the second group

OTHERMicroneedling with topical application of saline

Microneeling preformed onto the scar In one group insulin will be applied while saline will be used in the second group

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE (Subject)

Eligibility

Sex/Gender

ALL

Age

12 Years to 60 Years

Healthy volunteers

Inclusion criteria

1. Patients aged 12 to 60 years 2. Atrophic scars (traumatic or surgical) 3. Completely healed scars

Exclusion criteria

1. Patients with a tendency or history of hypertrophic or keloidal scars 2. Patients who received treatment for their scar in the past 3 months 3. Diabetic patients or those with a history of Dysglycemia 4. Pregnant, or lactating females 5. Patients with active infection at the site of scar 6. Patients currently receiving isotretinoin treatment or in the past month

Design outcomes

Primary

Measure	Time frame	Description
Change in Scar	4 months	According the different scar assessment scores (e.g.POSAS score - The Patient and Observer Scar Assessment Scale score, range from 6 to 60, the higher the score the worse the scar, lowering in the score denotes improvement )

Countries

Egypt

Contacts

Primary ContactDalia I Halwag, PhD, MD

daliahalwag@gmail.com+00201224489473

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026